| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/08/2004 | WO2004002985A1 Peptidic thrombin inhibitor compound |
| 01/08/2004 | WO2004002944A1 Inhibitors of hcv ns5b polymerase |
| 01/08/2004 | WO2004002940A1 Inhibitors of hcv ns5b polymerase |
| 01/08/2004 | WO2004002574A1 Method for the prophylaxis and therapy of mycoses in fish and invertebrates and the development stages thereof |
| 01/08/2004 | WO2004002535A1 Use of an npy y2 receptor antagonist for treating disorders related to angiogenesis |
| 01/08/2004 | WO2004002534A1 Use of dimethyl sulfone as isotonicity agent |
| 01/08/2004 | WO2004002532A1 Mkk7 activation inhibitor |
| 01/08/2004 | WO2004002526A1 Co-administration of cg250 and il-2 or ifn-alpha for treating cancer such as renal cell carcinomas |
| 01/08/2004 | WO2004002520A1 Method and kit for the tolerance induction to allergy-causing substances, and the tolerance achievment against the substances thereby |
| 01/08/2004 | WO2004002519A1 Methods of treating or preventing ibd with il-18 |
| 01/08/2004 | WO2004002518A1 Prevention, therapy and prognosis/monitoring in sepsis and septic shock |
| 01/08/2004 | WO2004002517A1 Diagnostics/preventives/re medies for respiratory diseases |
| 01/08/2004 | WO2004002514A1 Preventives/remedies for cancer |
| 01/08/2004 | WO2004002513A2 Proteins involved in the regulation of energy homeostasis |
| 01/08/2004 | WO2004002512A1 Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes |
| 01/08/2004 | WO2004002511A1 Anti-hiv agent |
| 01/08/2004 | WO2004002510A1 Novel use of lipopeptide preparations |
| 01/08/2004 | WO2004002509A2 Use of casein peptides for treating hypertension |
| 01/08/2004 | WO2004002502A1 Botulinum toxins for treating priapism |
| 01/08/2004 | WO2004002500A1 Method of treating autoimmune diseases with interferon-beta and il-2r antagonist |
| 01/08/2004 | WO2004002492A1 Use of vasopeptidase inhibitors in the treatment of nephropathy |
| 01/08/2004 | WO2004002459A1 Hollow nanoparticle having modified cysteine residue and drug with the use thereof |
| 01/08/2004 | WO2004002456A1 Biodegradable block copolymeric compositions for drug delivery |
| 01/08/2004 | WO2004002440A1 Cosmetic composition for the skin containing melanotan ii and the use thereof as a suntan preparation |
| 01/08/2004 | WO2004002424A2 Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses |
| 01/08/2004 | WO2004002422A2 2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
| 01/08/2004 | WO2004002421A2 Method for the treatment of multiple sclerosis |
| 01/08/2004 | WO2004002418A2 Compositions and methods comprising protein activated receptor antagonists |
| 01/08/2004 | WO2004002417A2 Mammalian ch1 deleted mimetibodies, compositions, methods and uses |
| 01/08/2004 | WO2004002416A2 Methods and materials for treating human papillomavirus infections |
| 01/08/2004 | WO2004002415A2 Compositions and methods for modulating a cytotoxic t lymphocyte immune response |
| 01/08/2004 | WO2004002404A2 Compositions and method for enhanced mucosal delivery of interferon beta |
| 01/08/2004 | WO2004002401A2 Caspase inhibitors for the treatment of diseases and conditions caused by exposure to radionuclides, biological agents, or chemical agents |
| 01/08/2004 | WO2004002367A1 Drug eluting stent |
| 01/08/2004 | WO2004002296A2 Therapeutic methods for reducing fat deposition and treating associated conditions |
| 01/08/2004 | WO2004002253A1 Necktie wearing-device |
| 01/08/2004 | WO2004002241A1 Satiety inducing composition |
| 01/08/2004 | WO2003097857A3 Method for the detection of aquaretic compounds |
| 01/08/2004 | WO2003095484A3 Polypeptides increasing p53 expression |
| 01/08/2004 | WO2003092647A3 Transport system in biological systems |
| 01/08/2004 | WO2003092579A3 Compositions and methods for treating cancer with an oncolytic viral agent |
| 01/08/2004 | WO2003091387A3 Non-invasive delivery of polypeptides through the blood-brain barrier, and in vivo selection of endocytotic ligands |
| 01/08/2004 | WO2003087139A3 Treatment of gastroparesis |
| 01/08/2004 | WO2003086178A3 Methods for inhibiting vascular hyperpermeability |
| 01/08/2004 | WO2003085090A3 A human ribonucleotide reductase m2 subunit |
| 01/08/2004 | WO2003080103A8 Antagonists of megalin or cubilin for use in preventing organ damage induced by therapeutic agents |
| 01/08/2004 | WO2003078959A3 Methods for shp1 mediated neuroprotection |
| 01/08/2004 | WO2003078614A3 Gntiii (udp-n-acethylglucosamine:beta-d mannoside beta (1,4)-n-acethylglucosaminy ltransferase iii) expression in plants |
| 01/08/2004 | WO2003070969A3 RNA INTERFERENCE MEDIATED INHIBITION OF BCL2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 01/08/2004 | WO2003068812A3 Immune-modulating peptide made of s. aureus enterotoxin b |
| 01/08/2004 | WO2003068150A3 Methods of treating and diagnosing arthritis |
| 01/08/2004 | WO2003067262A3 Methods and compositions involving the hsp90 activator aha1 |
| 01/08/2004 | WO2003055531A8 A hemostatic kit, a method of preparing a hemostatic agent and a method of promoting hemostasis |
| 01/08/2004 | WO2003054194A3 Modified tridegins, production and use thereof as transglutaminase inhibitors |
| 01/08/2004 | WO2003050238A3 Receptor-targeted adenoviral vectors |
| 01/08/2004 | WO2003047618A3 Immunotherapeutic methods and systems |
| 01/08/2004 | WO2003043648A3 Sfcyr iib or sfcyr iii for the treatment of auto-immune diseases |
| 01/08/2004 | WO2003039382A3 System for processing tissue |
| 01/08/2004 | WO2003037256A3 Use of somatostatin receptor agonists in the treatment of human disorders of sleep hypoxia and oxygen deprivation |
| 01/08/2004 | WO2003027313A3 SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE |
| 01/08/2004 | WO2003022224A3 Cox-2 function and wound healing |
| 01/08/2004 | WO2003020876A3 Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof |
| 01/08/2004 | WO2003020205A3 Non-mammalian gnrh analogs and uses thereof in regulation of fertility and pregnancy |
| 01/08/2004 | WO2003016505A3 Kgf polypeptide compositions |
| 01/08/2004 | WO2003012057A3 Antisense modulation of serum amyloid a4 expression |
| 01/08/2004 | WO2003007890A3 Tropomyosin isoforms, and diagnostic and therapeutic uses therefor |
| 01/08/2004 | WO2003007800A3 Methods for diagnosing and treating diseases and conditions of the digestive system and cancer |
| 01/08/2004 | WO2003003018A3 Method for identifying compounds for the therapy of aging of the cardiovascular system |
| 01/08/2004 | WO2003000859A3 G-protein coupled receptors |
| 01/08/2004 | WO2002103016B1 Human tachykinin-related splice variants and compositions thereof |
| 01/08/2004 | WO2002099036A3 Inhibition of neurodegeneration |
| 01/08/2004 | WO2002095067A3 INTERFERON α-14 POLYMORPHISM |
| 01/08/2004 | WO2002095009A3 Nucleic acid and corresponding protein entitled 121p1f1 useful in treatment and detection of cancer |
| 01/08/2004 | WO2002092765A3 Novel telomerase inhibitors and uses therefor |
| 01/08/2004 | WO2002092623A8 INHIBITORS OF RECEPTOR ACTIVATOR OF NF-κB AND USES THEREOF |
| 01/08/2004 | WO2002091996A3 Methods for treating cancer |
| 01/08/2004 | WO2002083065A3 Peptide antiangiogenic drugs |
| 01/08/2004 | WO2002080952A3 Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways |
| 01/08/2004 | WO2002079448A3 G-protein coupled receptors |
| 01/08/2004 | WO2002078624A3 Aerosol administration of interleukin-2 liposomes |
| 01/08/2004 | WO2002072780A3 Igf antagonist peptides |
| 01/08/2004 | WO2002068650B1 Modified and stabilized gdf propeptides and uses thereof |
| 01/08/2004 | WO2002066654A3 Drug metabolizing enzymes |
| 01/08/2004 | WO2002064797A3 Mitochondrial topoisomerase i |
| 01/08/2004 | WO2002062372A3 Tripeptide derivatives for the treatment of postlesional diseases of the nervous system |
| 01/08/2004 | WO2002061059A3 Carbohydrate metabolism enzymes |
| 01/08/2004 | WO2002059310A3 Polynucleotides encoding cellular transporters and methods of use thereof |
| 01/08/2004 | WO2002055697A3 Human rhinovirus assays, and compositions comprising anti-rhinoviral perturbagens |
| 01/08/2004 | WO2002053594A3 Inhibitors of memapsin 2 and use thereof |
| 01/08/2004 | WO2002051989A3 Human 4-nitrophenylphosphatase |
| 01/08/2004 | WO2002050250A3 Signal-1/signal-2 bifunctional peptide inhibitors |
| 01/08/2004 | WO2002048397A3 Regulation of human adenylate cyclase, type vii |
| 01/08/2004 | WO2002046458A3 Nucleic acids of the human abca5, abca6, abca9, and abca10 genes, vectors containing such nucleic acids and uses thereof |
| 01/08/2004 | WO2002046225A3 Use of sarp-1 for the treatment and/or prevention of scleroderma |
| 01/08/2004 | WO2002046217A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 01/08/2004 | WO2002045737A3 Methods of treatment involving human mda-7 |
| 01/08/2004 | WO2002034776A3 Epitopes of pai-1 |
| 01/08/2004 | WO2001079524A3 Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof |
| 01/08/2004 | US20040006789 Pseudomonas syringae harpins, HopPtoP and HopPmaHpto, and their uses |
| 01/08/2004 | US20040006780 VEGF-modulated genes and methods employing them |